Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Pomalidomide
Drug ID BADD_D01798
Description Pomalidomide, an analogue of thalidomide, is an immunomodulatory antineoplastic agent. FDA approved on February 8, 2013.
Indications and Usage Pomalidomide is indicated for patients with multiple myeloma who have received at least two prior therapies including lenalidomide and bortezomib and have demonstrated disease progression on or within 60 days of completion of the last therapy.
Marketing Status approved
ATC Code L04AX06
DrugBank ID DB08910
KEGG ID D08976
MeSH ID C467566
PubChem ID 134780
TTD Drug ID D0A3ZU
NDC Product Code 65015-893; 17337-0068; 63069-404; 68554-0092; 70225-1106; 59572-501; 59572-502; 55111-989; 68554-0091; 82245-0108; 63069-402; 42973-232; 54893-0038; 59572-503; 59572-504; 63069-403
UNII D2UX06XLB5
Synonyms pomalidomide | CC-4047 | CC 4047 | CC4047 | Imnovid | Pomalyst | actimid
Chemical Information
Molecular Formula C13H11N3O4
CAS Registry Number 19171-19-8
SMILES C1CC(=O)NC(=O)C1N2C(=O)C3=C(C2=O)C(=CC=C3)N
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Immunosuppression10.03.02.0010.001206%Not Available
Lung neoplasm22.08.01.006; 16.19.04.0010.000362%Not Available
Large intestinal obstruction07.13.03.0030.000241%
Pigmentation disorder23.05.03.0010.002170%Not Available
Metabolic encephalopathy17.13.01.001; 14.11.01.0130.000482%Not Available
Renal impairment20.01.03.010--Not Available
Sinus disorder22.04.06.0020.013020%
Respiratory tract infection22.07.07.001; 11.01.08.017--Not Available
Unevaluable event08.01.03.0510.090779%Not Available
Non-cardiac chest pain22.12.02.009; 08.01.08.006--
Arterial occlusive disease24.04.02.0210.000964%Not Available
Increased upper airway secretion22.12.03.0070.000530%Not Available
Chest wall mass15.03.05.0060.000241%Not Available
Bowel movement irregularity07.02.03.0030.002459%Not Available
Solar lentigo23.05.01.0130.000820%Not Available
Exfoliative rash23.03.07.0060.000241%Not Available
Orthostatic hypertension24.08.02.010; 17.05.01.0180.000820%Not Available
Loose tooth07.09.05.0090.001350%Not Available
Bone loss15.02.04.0200.001181%Not Available
Bronchial hyperreactivity22.03.01.0160.000241%Not Available
Cytopenia01.03.03.0120.009862%Not Available
Adverse reaction08.06.01.0180.008680%Not Available
Oral disorder07.05.01.0050.004485%Not Available
Oropharyngeal pain07.05.05.004; 22.12.03.016--
Acute kidney injury20.01.03.016--
Upper-airway cough syndrome22.12.03.0360.002700%
Intraductal proliferative breast lesion21.05.01.014; 16.10.01.0060.000241%Not Available
Pneumocystis jirovecii pneumonia11.03.07.005; 22.07.08.009--Not Available
Mouth swelling23.04.01.020; 10.01.05.020; 07.05.04.0070.001760%Not Available
Respiratory symptom22.12.02.0130.002170%Not Available
The 14th Page    First    Pre   14 15 16    Next   Last    Total 16 Pages